The company’s proprietary EpiTAC platform is a modular antibody-based system that enables the precise degradation of disease-driving membrane and extracellular proteins in a tissue-specific manner.

EpiBiologics launched in March 2023 with $50 million in Series A funding, which will enable the company to expand its validation of the platform, advance its pipeline of drug candidates, and further expand its team.